Shots:

• Mycenax to sell LusiNEX project- including cell banks- CMC technology- intellectual properties- and clinical trial results to Gedeon Richter making a total deal value $16.5M. Mycenax to get payments as it completes the stages of asset transfer which will be utilized to operation and facility expansion which further strengthen Mycenax’s capacities in CDMO business
• The focus of the agreement is to fully focus on its CDMO business and become one of the CDMO companies in Asia
• LusiNEX is a biosimilar product of Actemra/ RoActemra and has completed its P-I demonstrating bioequivalence in 2018 and is expected to enter in P-III trial while further receiving market approval

Click here to read full press release/ article | Ref: Mycenax | Image: Pharmaworld